跳至主要内容
临床试验/ISRCTN10001405
ISRCTN10001405进行中(未招募)未知

Prospective Evaluation of AI R&D tool for patient stratification - Trial for Renal immuno-oncology model Experimental Evaluation (PEAR-TREE)

Ourotech Limited (trading as Pear Bio)0 个研究点目标入组 20 人开始时间: 2022年10月14日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Aged 18 years old and over
  • 2. Patients with operable kidney cancer
  • 3. Able to give informed consent
  • 4. Able to give 40 ml of blood and surgical sample yields >= 0.4 g of cancerous tissue

排除标准

  • 1. Inoperable or metastatic kidney cancer
  • 2. Pre-operative haemoglobin levels below 120g/l
  • 3. Patients who have already commenced chemotherapy, targeted therapy, immunotherapy or radiotherapy
  • 4. Recurrence of cancer from any other site than the kidney
  • 5. Any other disease or finding that renders the patient at high risk of treatment complications or interferes with obtaining informed consent

研究者

发起方
Ourotech Limited (trading as Pear Bio)

相似试验